



Fig. 1

Control



Compound I



SLIGRL





Fig. 1. Control, Compound I, and SLIGRL treated cells. The cells were stained with toluidine blue and photographed under a light microscope.

Fig. 2

Control



Cpd.I



SLIGRL





Figure 2 shows three fluorescence microscopy images of cells treated with different compounds. The Control image shows a bright, crescent-shaped structure. The Cpd.I image shows a similar structure but with some additional bright spots. The SLIGRL image shows a bright, irregularly shaped structure surrounded by many small bright spots.

Fig. 3

Control




STI



SLIGRL



Fig. 4A



Downloaded from www.sciencedirect.com

Fig. 4B






Fig. 5A

Control



SLIGRL



STI



Cpdl






Figure 5B

Control



SLIGRL



CpdI



Fig. 6A


Control



SLIGRL



CpdI



Downloaded from www.jci.org on June 1, 2015

Fig. 6B





Fig. 7A

Control



SLIGRL

Fig. 7B

Control



SLIGRL




Fig. 7C

Control



STI






Figure 8

Control



SH00230



SLIGRL




Figure 9





Figure 10

Control



Anti ICAM-1 antibody




FIG. 11

